EYEPOINT PHARMAC. DL-01
EyePoint Pharmaceuticals, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases com… Read more
Market Cap & Net Worth: EYEPOINT PHARMAC. DL-01 (PV3B)
EYEPOINT PHARMAC. DL-01 (F:PV3B) has a market capitalization of $975.56 Million (€950.40 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #8597 globally and #921 in its home market, demonstrating a -23.08% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying EYEPOINT PHARMAC. DL-01's stock price €11.48 by its total outstanding shares 82787220 (82.79 Million).
EYEPOINT PHARMAC. DL-01 Market Cap History: 2015 to 2026
EYEPOINT PHARMAC. DL-01's market capitalization history from 2015 to 2026. Data shows change from $3.56 Billion to $975.56 Million (-9.99% CAGR).
EYEPOINT PHARMAC. DL-01 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how EYEPOINT PHARMAC. DL-01's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of PV3B by Market Capitalization
Companies near EYEPOINT PHARMAC. DL-01 in the global market cap rankings as of March 19, 2026.
Key companies related to EYEPOINT PHARMAC. DL-01 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
EYEPOINT PHARMAC. DL-01 Historical Marketcap From 2015 to 2026
Between 2015 and today, EYEPOINT PHARMAC. DL-01's market cap moved from $3.56 Billion to $ 975.56 Million, with a yearly change of -9.99%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €975.56 Million | -24.12% |
| 2025 | €1.29 Billion | +126.56% |
| 2024 | €567.49 Million | -68.50% |
| 2023 | €1.80 Billion | +558.39% |
| 2022 | €273.63 Million | -70.99% |
| 2021 | €943.26 Million | +151.70% |
| 2020 | €374.76 Million | -66.59% |
| 2019 | €1.12 Billion | -12.00% |
| 2018 | €1.27 Billion | +73.81% |
| 2017 | €733.37 Million | -45.03% |
| 2016 | €1.33 Billion | -62.57% |
| 2015 | €3.56 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of EYEPOINT PHARMAC. DL-01 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $975.56 Million USD |
| MoneyControl | $975.56 Million USD |
| MarketWatch | $975.56 Million USD |
| marketcap.company | $975.56 Million USD |
| Reuters | $975.56 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.